Literature DB >> 19244472

Recombinant vesicular stomatitis virus expressing influenza nucleoprotein induces CD8 T-cell responses that enhance antibody-mediated protection after lethal challenge with influenza virus.

Brice E Barefoot1, Christopher J Sample, Elizabeth A Ramsburg.   

Abstract

Live attenuated vaccine vectors based on recombinant vesicular stomatitis viruses (rVSVs) expressing foreign antigens are highly effective vaccines in animal models. In this study, we report that an rVSV expressing influenza nucleoprotein (VSV NP) from the first position of the VSV genome induces robust anti-NP CD8 T cells in immunized mice. These CD8 T cells are phenotypically similar to those induced by natural influenza infection and are cytotoxic in vivo. Animals immunized with an rVSV expressing the influenza hemagglutinin (rVSV HA) were protected but still exhibited considerable morbidity after challenge. Animals receiving a cocktail vaccine of rVSV NP and rVSV HA had reduced pulmonary viral loads, less weight loss, and reduced clinical signs of illness after influenza virus challenge, relative to those vaccinated with rVSV HA alone. Influenza NP is a highly conserved antigen, and induction of protective anti-NP responses may be a productive strategy for generating heterologous protection against divergent influenza strains.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19244472      PMCID: PMC2668267          DOI: 10.1128/CVI.00451-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  34 in total

1.  An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.

Authors:  N F Rose; P A Marx; A Luckay; D F Nixon; W J Moretto; S M Donahoe; D Montefiori; A Roberts; L Buonocore; J K Rose
Journal:  Cell       Date:  2001-09-07       Impact factor: 41.582

2.  Diminished primary and secondary influenza virus-specific CD8(+) T-cell responses in CD4-depleted Ig(-/-) mice.

Authors:  J M Riberdy; J P Christensen; K Branum; P C Doherty
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

3.  A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus.

Authors:  Sukumar Saha; Shinsuke Yoshida; Kenji Ohba; Kiyohiko Matsui; Tomoko Matsuda; Fumihiko Takeshita; Kazunori Umeda; Yuichi Tamura; Kentaro Okuda; Dennis Klinman; Ke-Qin Xin; Kenji Okuda
Journal:  Virology       Date:  2006-08-30       Impact factor: 3.616

4.  Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

Authors:  Robert L Atmar; Wendy A Keitel; Shital M Patel; Jacqueline M Katz; Dewei She; Hana El Sahly; Justine Pompey; Thomas R Cate; Robert B Couch
Journal:  Clin Infect Dis       Date:  2006-09-25       Impact factor: 9.079

5.  Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial.

Authors:  A Cerwenka; T M Morgan; R W Dutton
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

6.  Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

Authors:  Jiangtao Lin; Jiansan Zhang; Xiaoping Dong; Hanhua Fang; Jiangting Chen; Nan Su; Qiang Gao; Zhenshan Zhang; Yuxuan Liu; Zhihong Wang; Meng Yang; Ruihua Sun; Changgui Li; Su Lin; Mei Ji; Yan Liu; Xu Wang; John Wood; Zijian Feng; Yu Wang; Weidong Yin
Journal:  Lancet       Date:  2006-09-16       Impact factor: 79.321

7.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Authors:  K G Nicholson; A E Colegate; A Podda; I Stephenson; J Wood; E Ypma; M C Zambon
Journal:  Lancet       Date:  2001-06-16       Impact factor: 79.321

8.  Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.

Authors:  Jennifer A Schwartz; Linda Buonocore; Anjeanette Roberts; Amorsolo Suguitan; Darwyn Kobasa; Gary Kobinger; Heinz Feldmann; Kanta Subbarao; John K Rose
Journal:  Virology       Date:  2007-05-23       Impact factor: 3.616

9.  Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.

Authors:  Amorsolo L Suguitan; Josephine McAuliffe; Kimberly L Mills; Hong Jin; Greg Duke; Bin Lu; Catherine J Luke; Brian Murphy; David E Swayne; George Kemble; Kanta Subbarao
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

10.  Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens.

Authors:  Dominick J Laddy; Jian Yan; Michele Kutzler; Darwyn Kobasa; Gary P Kobinger; Amir S Khan; Jack Greenhouse; Niranjan Y Sardesai; Ruxandra Draghia-Akli; David B Weiner
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

View more
  12 in total

1.  Heterologous prime-boost immunization with vesiculovirus-based vectors expressing HBV Core antigen induces CD8+ T cell responses in naïve and persistently infected mice and protects from challenge.

Authors:  Carolina Chiale; Safiehkhatoon Moshkani; John K Rose; Michael D Robek
Journal:  Antiviral Res       Date:  2019-05-30       Impact factor: 5.970

Review 2.  Rhabdoviruses as vectors for vaccines and therapeutics.

Authors:  Gabrielle Scher; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2020-10-29       Impact factor: 7.090

3.  Intranasal administration of adeno-associated virus type 12 (AAV12) leads to transduction of the nasal epithelia and can initiate transgene-specific immune response.

Authors:  Kathrina Quinn; Mary R Quirion; Chia-Yun Lo; Julia A Misplon; Suzanne L Epstein; John A Chiorini
Journal:  Mol Ther       Date:  2011-08-09       Impact factor: 11.454

Review 4.  Developments of subunit and VLP vaccines against influenza A virus.

Authors:  Ma-ping Deng; Zhi-hong Hu; Hua-lin Wang; Fei Deng
Journal:  Virol Sin       Date:  2012-06-09       Impact factor: 4.327

5.  Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.

Authors:  Alaina J Mooney; S Mark Tompkins
Journal:  Future Virol       Date:  2013-01-01       Impact factor: 1.831

6.  Intramuscular immunization with a vesicular stomatitis virus recombinant expressing the influenza hemagglutinin provides post-exposure protection against lethal influenza challenge.

Authors:  Brice E Barefoot; Kathleen Athearn; Christopher J Sample; Elizabeth A Ramsburg
Journal:  Vaccine       Date:  2009-10-09       Impact factor: 3.641

7.  CD8+ T cell landscape in Indigenous and non-Indigenous people restricted by influenza mortality-associated HLA-A*24:02 allomorph.

Authors:  Luca Hensen; Patricia T Illing; E Bridie Clemens; Thi H O Nguyen; Marios Koutsakos; Carolien E van de Sandt; Nicole A Mifsud; Andrea T Nguyen; Christopher Szeto; Brendon Y Chua; Hanim Halim; Simone Rizzetto; Fabio Luciani; Liyen Loh; Emma J Grant; Phillipa M Saunders; Andrew G Brooks; Steve Rockman; Tom C Kotsimbos; Allen C Cheng; Michael Richards; Glen P Westall; Linda M Wakim; Thomas Loudovaris; Stuart I Mannering; Michael Elliott; Stuart G Tangye; David C Jackson; Katie L Flanagan; Jamie Rossjohn; Stephanie Gras; Jane Davies; Adrian Miller; Steven Y C Tong; Anthony W Purcell; Katherine Kedzierska
Journal:  Nat Commun       Date:  2021-05-18       Impact factor: 14.919

8.  Acute reactogenicity after intramuscular immunization with recombinant vesicular stomatitis virus is linked to production of IL-1β.

Authors:  Kathleen Athearn; Christopher J Sample; Brice E Barefoot; Kristi L Williams; Elizabeth A Ramsburg
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

9.  Protective effector memory CD4 T cells depend on ICOS for survival.

Authors:  Tamson V Moore; Bryan S Clay; Caroline M Ferreira; Jesse W Williams; Magdalena Rogozinska; Judy L Cannon; Rebecca A Shilling; Amanda L Marzo; Anne I Sperling
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

Review 10.  Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines.

Authors:  Marine L B Hillaire; Albert D M E Osterhaus; Guus F Rimmelzwaan
Journal:  J Biomed Biotechnol       Date:  2011-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.